BioIntelliSense Announces FDA Clearance of the BioButton® Multi-Patient Wearable and BioDashboard™
BioIntelliSense expands its portfolio of continuous monitoring solutions with the rechargeable and reusable FDA-cleared BioButton® Multi-Patient wearable and BioDashboard™ clinical intelligence system for scalable exception management and automated vital sign collection.
Recent News
BioIntelliSense Partners with Hicuity Health
The new partnership integrates the BioIntelliSense medical-grade BioButton® wearable and BioDashboard™ clinical intelligence solution with Hicuity Health’s robust patient monitoring services to scale virtual care programs from in-hospital to home….
BioIntelliSense Announces Observational Study in Journal of Clinical Medicine
The large-scale study of nearly 12,000 hospitalized patients highlights continuous multiparameter vital sign monitoring resulted in significant positive impact on patient outcomes BioIntelliSense, a continuous health monitoring and clinical intelligence…
BioIntelliSense Announces FDA Clearance of the BioButton® Multi-Patient Wearable and BioDashboard™
BioIntelliSense, a continuous health monitoring and clinical intelligence company, announces FDA clearance of the rechargeable BioButton® Multi-Patient wearable and BioDashboard™ system to cost-effectively grow and scale hospital virtual care programs….
BioIntelliSense Announces Completion of Houston Methodist Inpatient Expansion of the BioButton
The BioIntelliSense FDA-cleared BioButton® multiparameter wearable is now monitoring tens of thousands of patients across more than 2,600 non-ICU beds across Houston Methodist as part of the leading healthcare system’s…
Ardent Health Services and BioIntelliSense Launch Continuous Inpatient Monitoring Initiative
Ardent Health Services and BioIntelliSense, today announced the launch of a new continuous patient monitoring initiative to empower clinicians with greater data-driven insights for patient care and to optimize clinical…
BioIntelliSense Acquires Alertwatch Clinical Intelligence Engine
BioIntelliSense, a continuous health monitoring and clinical intelligence company, today announced its acquisition of AlertWatch®, an FDA-cleared, clinically proven patient monitoring solution. AlertWatch uniquely provides robust integration, data analysis and…